Anti-annexin antibodies, cholesterol levels and disability in multiple sclerosis.
So far, no studies have been conducted to evaluate possible correlations between lipid/lipoprotein levels and the anti-phospholipid antibody (aPL) positivity in multiple sclerosis (MS). In this cross-sectional study, we aimed to investigate the relationships between serum lipid profile and aPL positivity rates in MS patients, and their possible differences among secondary-progressive MS (SPMS) patients, relapsing-remitting MS patients in remission (REM) and in relapse (REL). We included 16 SPMS, 58 REM and 26 REL. Their sera were tested for aPL (anti-cardiolipin, anti-β2glycoproteinI, anti-prothrombin, anti-annexinV), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and lipoprotein(a) levels. High TC levels were more frequent in SPMS patients than other groups (p=0.05). The REL had significantly higher rates of positivity for anti-β2glycoproteinI IgM (p<0.0001), anti-prothrombin IgG and IgM (both p=0.05) than the other groups. A significant positive correlation was found between age and both TC and LDL-C, disability and both TC and LDL-C, disease duration and LDL-C. TC levels were significantly higher (p=0.007) in anti-annexinV-IgG positive patients. The anti-annexinV-IgG positivity significantly associated with high levels of TC (p=0.002) and LDL-C (p=0.03). Our results support the hypothesis that both thrombogenic and neurodegenerative mechanisms associated with an abnormal cholesterol homeostasis might contribute to MS progression. Our study may have interesting practical implications, which could potentially open new therapeutic approaches in the context of appropriately designed clinical trials.
Clinical Pathology, Regina Elena National Cancer Institute, IFO, Rome, Italy.
Chiara
C
Mandoj
Multiple Sclerosis Center, Neurology Unit, Regina Elena National Cancer Institute, IFO, Rome, Italy.
Rosaria
R
Renna
Multiple Sclerosis Center, Neurology Unit, Regina Elena National Cancer Institute, IFO, Rome, Italy.
Domenico
D
Plantone
Biostatistic Unit, Regina Elena National Cancer Institute, IFO, Rome, Italy.
Isabella
I
Sperduti
Clinical Pathology, Regina Elena National Cancer Institute, IFO, Rome, Italy.
Giovanni
G
Cigliana
Clinical Pathology, Regina Elena National Cancer Institute, IFO, Rome, Italy.
Laura
L
Conti
Multiple Sclerosis Center, Neurology Unit, Regina Elena National Cancer Institute, IFO, Rome, Italy. Electronic address: tatiana.koud@gmail.com.
Tatiana
T
Koudriavtseva
D000328:Adult; D017304:Annexin A5 / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood*; D002308:Cardiolipins / Q000276:immunology; D002784:Cholesterol / Q000097:blood*; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000276:immunology* / Q000378:metabolism* / Q000503:physiopathology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D011516:Prothrombin / Q000276:immunology; D055815:Young Adult; D053482:beta 2-Glycoprotein I / Q000276:immunology
D017304:Annexin A5; D001323:Autoantibodies; D002308:Cardiolipins; D053482:beta 2-Glycoprotein I; D011516:Prothrombin; D002784:Cholesterol
Anti-annexin; Anti-phospholipid antibodies; Cholesterol; Multiple sclerosis